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Predicting disease outcome is becoming increasingly important in
understanding the natural history of breast cancer, planning treat-
ment strategies and counselling the patient. Assessment of certain
prognostic ‘markers’ or ‘factors’ is now routine in the pathological
examination of breast tumours, in order to give an indication of
suitability of certain forms of treatment, the risk of recurrence and
expected length of survival (Royal College of Pathologist Working
Group, 1991). Some of the more traditional markers include histo-
logical typing and grading, primary tumour size, lymph node
stage, vascular invasion and excision margin status. Numerous
putative novel prognostic markers have been identified in recent
years through increasing understanding of the biology of breast
cancer. One group of these possible factors is the Cadherin family. 
Epithelial cadherin (E-cadherin) is a member of the cadherin
family of cell adhesion molecules, joining adjacent epithelial
cells together via a Ca2+-dependent homophilic binding mechanism
(Rasbridge et al, 1993). The cytoplasmic domain of E-cadherin (E-
CD) complexes with cytoplasmic proteins known as catenins,
which links the cadherin with the cytoskeleton and other transmem-
brane proteins (Kemler, 1993). E-CD mutants with deletion of the
catenin-binding domain cannot bind cells together, so catenins are
crucial to cadherin function (Kemler, 1993; Hashizume et al, 1996).
Cadherins are also considered to be of importance in embryonic
development and maintenance of adult tissue architecture, as
inactivation of other adhesion systems has little impact if cadherins
are fully functional (Van der Wurff et al, 1992; Siitonen et al, 1996). 
Several lines of evidence suggest that loss of cell–cell adhesion
contributes to the detachment of tumour cells and allows them to
transgress normal barriers and migrate to distant sites. To that end
collagen invasion assays have shown that cells expressing E-CD
were non-invasive, whereas E-CD-negative cells were invasive.
Down-regulation of E-CD protein by antisense RNA induced
invasive behaviour in previously non-invasive cells (Behrens,
1993). In addition, a transgenic mouse model of pancreatic β cell
carcinoma revealed that loss of E-CD expression coincided with
transition from well differentiated adenoma to invasive carcinoma
(Perl et al, 1998). However, some studies have indicated that the
loss of E-CD is reversible, for example in ras-transformed Madin
Darby Canine kidney cells in nude mice, possibly due to interac-
tion with the host environment (Mareel et al, 1991). Dysfunction
of α -catenin has also been implicated. Shimoyama et al (1992)
found that a human lung cancer cell line strongly expressed E-CD,
but showed reduced E-CD adhesive function. This cell line did not
express α -catenin. Some experiments have also indicated that the
function of E-CD can be regulated by external factors. For
example, tamoxifen restored E-CD function in the MCF-7 breast
cancer cell line and inhibited invasion (Bracke et al, 1994). 
In the breast, several studies have reported a difference in E-CD
expression in carcinoma compared to normal tissue. E-CD expres-
sion in ductal carcinoma in situ (DCIS) is similar to that of normal
tissue, while invasive ductal carcinomas may have reduced or
heterogeneous expression. In contrast, infiltrating lobular carcinoma
(ILC) has significantly reduced or absent expression (Gamallo et al,
1993; Oka et al, 1993; Rasbridge et al, 1993; Birchmeier and
Behrens, 1994; Lipponen et al, 1994; Siitonen et al, 1996; Charpin
et al, 1997; Gonzalez et al, 1999). The reduced expression seen in
ILC is assumed to be reflected in the different pattern of invasion
compared to ductal and special types of breast cancer. 
A number of studies have found correlations between reduced
E-CD levels and certain features, such as high grade, loss of
oestrogen receptor (ER) and progesterone receptor (PR), axillary
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node metastases, recurrence, mutated p53 and growth fraction
(Siitonen et al, 1996; Hashizume et al, 1996; Charpin et al, 1997;
Gupta et al, 1997). Some (Gamallo et al, 1993; Lipponen et al,
1994; Gonzalez et al, 1999) have observed a relationship with
histological grade and tumour type, but no other features. Maguire
et al (1997), detecting E-CD by ELISA found no relationship with
tumour size, node status or ER, but did associate early recurrence
with lower E-CD levels. Siitonen et al (1996) proposed that E-CD
expression was directly related to progression. Many studies have
concluded that E-CD alteration appears to be involved more in
invasion and less with metastatic potential than previously
suggested and that perhaps other factors, in addition to loss of cell
adhesion, are involved in the complex process of metastasis. 
In this study we have examined the expression of E-CD in a
consecutive series of patients with well characterised primary
breast cancer and long-term clinical follow up to provide data on
relationships between E-CD expression, primary tumour charac-
teristics and behaviour. 
METHODS 
Patients 
A cohort of patients presenting consecutively with primary oper-
able breast cancer was selected randomly from archives of the
Nottingham/Tenovus Primary Breast Cancer Series. All patients
were treated by a single surgeon (RW Blamey, Nottingham City
Hospital), by mastectomy or wide local excision but in this histor-
ical series received no adjuvant therapy. Loco-regional lymph
nodes were sampled. Patients were reviewed at 3 monthly inter-
vals for 18 months after surgery, then 6 monthly for the next 5
years and yearly thereafter. Data on recurrence, distant metastases
and survival, menopausal status, histological grade (Elston and
Ellis, 1991), tumour type (Ellis et al, 1992), vascular invasion
(Pinder et al, 1994), age of patient at diagnosis, primary tumour
size, prognostic group (Pereira et al, 1995) and ER status was
recorded and stored on a computer database. 
This study included 174 primary operable breast cancer cases,
with age of patient ranging from 28–70 years (mean 55 years).
Follow up ranged from 7 to 205 months (median 102 months). 
Materials 
Immunohistochemistry was performed on paraffin-embedded
tissue sections, using the standard streptavidin–biotin–peroxidase
complex method. The monoclonal mouse anti-E-cadherin anti-
body (HECD-1) was supplied by Zymed Laboratories Inc (San
Francisco, California, USA). The StreptABC kit used to detect the
primary antibody was obtained from Dako Ltd (High Wycombe,
Buckinghamshire, UK). The DAB developing solution and the
phosphate-citrate buffer with sodium perborate used to dilute the
DAB were purchased from Sigma-Aldrich Co Ltd (Poole, Dorset,
UK). The 3-aminopropyl-triethoxysilane (TESPA) coating on the
microscope slides was also supplied by Sigma-Aldrich Co Ltd. 
The primary antibody was diluted to 1 in 400 by a 1/5 solution of
NSS (normal swine serum in tris-buffered saline). Tissue sections
were treated by microwave retrieval prior to staining. Known posi-
tive controls (composite breast tissue) were included with each
batch to ensure interbatch reproducibility. Portions of normal tissue
within the tumour sections provided internal controls. Negative
controls consisted of sections not incubated with primary
antibody. 
Assessment of staining 
The approximate intensity of E-CD membrane staining of tumour
cells was classified as absent (0), weak, but focal (1), weak (2) or
strong (3). The weak, but focal, classification was added following
pilot studies showing a small number of sections had small weak
areas of staining in an otherwise negative tumour. The approxi-
mate fraction of tumour cells with membrane staining was also
evaluated and divided into 4 categories 0%, less than 25%,
25–75% and greater than 75%. 
The 174 tumours were analysed at least twice, until intraob-
server agreement was reached and agreement achieved in difficult
cases by consensus following assessment by a second observer.
All the data obtained (E-CD assessment and patient information)
was analysed on an Apple Macintosh computer, using the Statview
4.1 programme. Statistical significance was calculated using the χ 2
tests and Fisher’s exact test where appropriate. Survival analysis
was performed by applying the log-rank test of significance to
Kaplan–Meier cumulative survival curves. 
RESULTS 
Assessment of staining 
In both positive controls and internal areas of normal breast tissue
the immunostaining was clear around the membrane with minimal
background reactivity (Figure 1). The membranes of epithelial
cells lining the ducts and lobules of normal breast tissue were
strongly and uniformly stained. Myoepithelial cells exhibited
weaker staining. E-CD expression could be extremely variable
within the same tumours, with differing levels of intensity
throughout some tumours. In such cases, the predominant pattern
was recorded. Variation in the proportion of cells stained was also
occasionally seen, with negative areas interspersed in otherwise
positive tumours. Small islands of weakly stained cells were also
observed in otherwise negative tumours. Only membrane staining
was evaluated, but it was noticed that a significant number of
tumours (especially those with weaker staining) had diffuse
staining within the cytoplasm. In a very small proportion of cases,
staining was prominent around the nucleus of the tumour cell. 
Distribution of E-cadherin expression and analysis of
staining 
Proportion and intensity were scored separately. In order to further
examine E-CD expression and to determine whether there was an
Figure 1 Photomicrograph of a E-CD positive primary breast cancer 1960 C Parker et al 
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association with biological and clinical variables, a combined score
of intensity and proportions was derived (range 0–4) (Tables 1
and 2). Using this approach, cases were placed into 4 distinct groups
showing no reactivity (0), weak and heterogeneous (1), weak and
homogeneous (2), strong and heterogeneous (3) and strong and
homogeneous (4) expression. The majority of (66%) tumours had
some reduction in expression, but few were completely absent. 74%
showed reduced expression when compared to the strong and
uniform levels of expression seen in normal epithelium. 
Table 1 Patterns of expression of E-cadherin intensity and proportion 
Proportion 0% < 25% 25–50% > 75% Total 
Intensity 
0 18 0 0 0 18 
10 13 0 0 13 
20 12 52 20 84 
30 5 28 26 59 
Total 18 30 80 46 174 
χ 2 = 248.1, P < 0.001. 
Table 2 Method of assignment of overall score for E-cadherin positivity 
Proportion 0 1 2 3 
Intensity (0%) (< 25%) (25–50%) (> 75%) 
Combined 0 0,0 
Proportion 1 1,1 
Intensity 2 2,1 2,2 2,3 
Score 3 3,2 3,3 
Key to intensity/proportion groups when grouped together (combinations in
brackets are derived from the numbers in bold in Table 1): 
(0,0) = 0 (negative) 
(1,1/2,1/2,2) = 1 (weak and heterogenous) 
(2,3) = 2 (weak and homogenous) 
(3,2) = 3 (strong and heterogenous) 
(3,3) = 4 (strong and homogenous). 
Table 3 Results of univariate analysis. E-cadherin vs other tumour and
patient variables 
χ 2 p 
Variable (#cases) 
Alive (93) vs Dead (73) 5.14 0.273 
Local recurrence 
Absent (97) vs Present (46) 8.43 0.077 
Regional recurrence 
Absent (93) vs Present (58) 1.35 0.853 
Distant metastasis 
Absent (77) vs Present (90) 2.50 0.645 
Menopausal status 
Pre- (53) vs Post (120) 5.42 0.247 
Age 
< 40 (13) vs 40–49(41) 
vs 50 or more (119) 6.39 0.604 
Size 
10 mm or less (14) vs 11–20 (85) 
vs 21–30 (54) vs > 30 (14) 9.79 0.634 
Grade 
1 (31) vs 2 (69) vs 3(66) 16.92 0.031 
Lymph node status 
Negative (98) vs Positive (69) 2.14 0.711 
Vascular invasion 
Absent (109) vs Present (30) 3.37 0.499 
Type 
Lobular (38) vs other (129) 30.60 < 0.001 
ER 
ER pos (< 10 fmol mg–1 prot) (70) vs 11.04 0.026 
ER neg (10 fmol mg–1 prot) (59) 
Table 4 Correlation histological grade
Intensity/ 0 1 2 3 4 Total
Proportion No. (%) No. (%) No. (%) No. (%) No. (%) No.
Grade 1 6 (19) 16 (52) 0 (0) 4 (13) 5 (16) 31 
2 8 (12) 30 (43) 7 (10) 10 (14) 14 (20) 69 
3 4 (6) 26 (39) 11 (17) 19 (29) 6 (9) 66 
T o t a l 1 87 21 83 32 5 1 6 6  
χ 2 = 16.92, P = 0.031. 
Intensity/Proportion: 0 – negative, 
1 – weak and heterogeneous, 
2 – weak and homogeneous, 
3 – strong and heterogeneous, 
4 – strong and homogeneous. 
Table 5 Correlation with ER status 
Intensity/ 0 1 2 3 4 Total 
Proportion No. (%) No. (%) No. (%) No. (%) No. (%) 
ER negative 4 (6) 36 (51) 7 (10) 18 (26) 5 (7) 70 
ER positive 8 (14) 21 (36) 8 (14) 9 (15) 13 (22) 59 
Total 12 57 15 27 18 129 
χ 2 = 11.04, P = 0.026. 
Intensity/Proportion: 0 – negative, 
1 – weak and heterogeneous, 
2 – weak and homogeneous, 
3 – strong and heterogeneous, 
4 – strong and homogeneous. 
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Analysis of intensity/proportion scores with other variables
(Table 3) showed only grade (P = 0.031), tumour type (P < 0.001)
(Table 4) and ER (P = 0.026) (Table 5) were associated with E-CD
immunoreactivity. There was no statistical difference between
overall survival of E-CD-positive and -negative patients (Figure 2). 
DISCUSSION 
Previous studies of E-cadherin expression in breast and other
cancers have varied widely in patient samples and scoring methods,
which make comparisons difficult. Most series (whether using
frozen or fixed tissue), including the present one, have shown that
the epithelial cells of normal ducts stain strongly and clearly around
the membrane (Gamallo et al, 1993; Moll et al, 1993; Rasbridge
et al, 1993; Birchmeier and Behrens 1994; Hashizume et al, 1996;
Gupta et al, 1997; Hunt et al, 1997). Oku et al (1993) noted that 80%
of frozen tumour sections with reduced E-CD expression were
heterogeneous (Oka et al, 1993). Charpin’s study (Charpin et al,
1997), also on frozen sections, noted that tumours with weaker
E-CD expression were heterogeneous. Studies on paraffin-
embedded tumours, as in this study, have also observed distinct
intratumoural variation in staining intensity (Lipponen et al, 1994). 
The diffuse cytoplasmic staining seen in this study has been
mentioned in other studies. Charpin et al (1997) and Siitonen et al
(1996) using frozen section material found that cytoplasmic staining
was present in some lobular-type tumours. We did not evaluate cyto-
plasmic staining in addition to membrane staining, as it was assumed
that any E-CD protein present in the cytoplasm was non-functional.
However, other studies have described E-CD cytoplasmic staining
based on the hypothesis that it may be new protein stored in the Golgi
apparatus or internalised for some reason (Rasbridge et al, 1993).
Alternatively, as cytoplasmic staining tends to be seen in tumours
with some loss of E-CD expression, there may be a defect in trans-
port mechanisms moving the protein to the membrane. A further
possibility involves the abnormal localisation or disruption of α -
catenin, which may fail to anchor the protein in the membrane. 
Direct comparisons of frequency distributions are not possible
due to differences in evaluating E-CD expression in different
series. Most studies report reductions in E-CD expression in a
significant number of breast carcinomas, ranging from 45% to
63% of cases (Oka et al, 1993; Rimm et al, 1995; Siitonen et al,
1996). However, the majority of the above studies were performed
on frozen tissue sections where staining is weaker than in paraffin-
embedded tissues (Lipponen et al, 1994). It appears that complete
loss of E-CD is uncommon, but the majority of tumours experi-
ence some reduction in E-CD expression. 
No correlations between E-CD expression and the following
features were found in this series: local recurrence, regional recur-
rence, distant metastases, lymph node status, vascular invasion,
tumour size, prognostic group or overall survival. There are
conflicting reports in the literature regarding the relationship of
E-CD expression with other prognostic factors and pathological
features, but local recurrence, vascular invasion and prognostic
group have not been reported as having any association with E-CD.
Siitonen et al (1996) and Oka et al (1993) found a correlation
between loss of E-CD and the presence of nodal metastases, but this
has not been widely reported (Gamallo et al, 1993; Lipponen et al,
1994; Charpin et al, 1997; Maguire et al, 1997). Oka et al (1993)
found an association between E-CD expression and metastatic
disease on frozen sections. Many studies do not have data available
on the development of distant metastases in patients with primary
breast carcinomas and further investigation is required. One study
(Oka et al, 1993) observed a relationship between E-CD and tumour
size. Our study, and most others have not found any correlation
(Gamallo et al, 1993; Lipponen et al, 1994; Siitonen et al, 1996;
Charpin et al, 1997; Maguire et al, 1997; Gonzalez et al, 1999). 
As in this series of paraffin-embedded material, several studies
on frozen section material have reported a correlation between
reduced E-CD expression and high histological grade (Gamallo
et al, 1993; Moll et al, 1993; Oka et al, 1993; Siitonen et al, 1996;
Charpin et al, 1997; Gonzalez et al, 1999). Others, also using
paraffin-embedded tissue, have however failed to find such a
correlation (Lipponen et al, 1994). Whilst the difference in
methodology may account for the discordance, more studies using
paraffin-embedded sections are clearly required. It is interesting
however, that when the data was analysed as a combined inten-
sity/proportion score, histological grade was statistically signifi-
cantly (P = 0.031) associated with E-CD immunohistochemical
expression. If, however, analysed independently as either intensity
or proportion alone there was no association found (data not
shown). Thus it is possible that this combined approach may
provide a more meaningful analysis of E-CD expression. 
Oestrogen is thought to regulate the expression of E-CD (Oka
et al, 1993). Indeed E-CD is not expressed in vitro in hormone
independent systems (Siitonen et al, 1996). If oestrogen enhances
expression of E-CD, loss of circulating oestrogen after the
menopause may result in reduction of E-CD to a certain extent.
However, in this study, menopausal status was not significantly
related to E-CD expression (P = 0.247), possibly as there was a
greater proportion of invasive lobular tumours (which are likely to
be E-CD negative) in postmenopausal women. 
A particularly interesting finding in this series was the relation-
ship between the proportion of E-CD-positive cells and the ER
status of the tumour (Table 5). ER-positive tumours tended to have
‘all or nothing’ E-CD expression and were predominantly in the
groups showing homogeneous staining either completely negative,
weak homogeneous or, more commonly, strong homogeneous
reactivity (scores 0, 1 or 4). ER-negative tumours had predomi-
nately heterogeneous expression, mostly a weak heterogeneous
(score 1) or strong heterogeneous (score 3) pattern of immunopos-
itivity being seen. Literature concerning the relationship between
E-CD expression and ER status is contradictory, with several
studies finding a correlation and yet others no association; our data
indicate that this may be related to the methodology of assessment
of positivity. Some studies have found that loss of E-CD is associ-
ated with loss of ER (Moll et al, 1993; Siitonen et al, 1996;
Charpin et al, 1997). These studies were all performed on frozen
tissue, while Lipponen’s work (Lipponen et al, 1994) using
paraffin-embedded tissue noted a correlation in the opposite orien-
tation (i.e. reduced E-CD was found in ER-positive tumours). In
the present study ER-positive tumours tended to be strongly
homogeneously positive compared to ER-negative tumours (22%
vs 7%). However ER-positive tumours were also more commonly
completely negative than those which were ER-negative (14% vs
6%). The relationship between E-CD and ER status may be influ-
enced and indeed confounded by tumour type; ER tends to be
retained in lobular cancers and as many of the E-CD-negative
tumours are of lobular morphology, many will contain ER. The
correlation between ER and E-CD warrants further evaluation. 
The loss of E-CD expression in lobular cancers is well docu-
mented in the literature and the present study also found that
lobular cancers were more likely to be E-CD negative. Classical1962 C Parker et al 
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lobular cancers tended to be almost always negative while lobular-
mixed types had staining in the mixed areas rather than the foci of
classical lobular architecture and morphology. This is consistent
with results obtained by Moll et al (1993). Cases of medullary and
mucinous carcinoma and DCIS were all found to be E-CD posi-
tive, which is supported by Lipponen et al (1994). Most studies,
including the present, have reported that invasive ductal
carcinomas were mainly E-CD positive, but expression was on
occasions reduced. The loss of expression in lobular carcinomas is
likely to be reflected in its distinct growth and invasion pattern.
Lobular cancers tend to grow infiltratively, as opposed to the
expansive pattern seen in many other cancers. Loss of E-CD could
lead to ‘looser’ intercellular connections, so cells can dissociate
from each other and invade in strands or clumps, resulting in the
characteristic ‘Indian file’ morphology seen histologically. 
E-cadherin expression is regulated through many mechanisms
such as gene mutation (Berx et al, 1996), methylation of its
promoter sequence (Hiraguri et al, 1998) as well as small G proteins,
DNA polymorphism and proteolysis. Recently 11 novel tumour-
associated E-CD mutations have been identified (Becker et al,
1999). This work has confirmed that E-CD mutations are associated
with morphological subtypes of gastric and breast cancers; specifi-
cally diffuse-type gastric cancers and invasive lobular of breast.
Tumour types differ in their prognosis, with classical lobular being
slightly more favourable than mixed lobular types (Pereira et al,
1995), but the prognosis of tumour type does not appear to be related
to E-CD. Tubular and mucinous types are E-CD positive and have
excellent prognoses, but medullary tumours also tend to be positive,
yet have an average prognosis (Ellis et al, 1992). Ductal carcinomas
have poor prognosis, but are mainly E-CD positive. In this context,
evaluating E-CD expression may be of some value in distinguishing
between pure lobular and mixed variants, as they are sometimes
difficult to identify; mixed portions will stain for E-CD. 
The use of immunohistochemistry does present some draw-
backs in that staining interpretation may be somewhat subjective.
It is also difficult to compare different series with different cut-offs
for positivity and negativity. Immunohistochemistry in general
does not determine if the protein being detected is functional or
mutated. E-CD is only one part of a complex system of cell
adhesion and genetic alterations in any component of this
cadherin–catenin complex can induce loss of adhesion function.
However, assessment of immunohistochemistry is the most readily
available technique for assessment of historical, archival paraffin-
embedded material in any worthwhile numbers. Thus it is only
with evaluation using this method that tumours from patients with
long-term follow up can be examined at present. Nevertheless, it
appears unlikely from these results that loss of E-CD is a key event
in the initiation of invasion (Moll et al, 1993; Lipponen et al,
1994). Additional factors, for example scatter factor, may act in
combination to damage cell adhesion and aid tumour cell detach-
ment and invasion (Meiners et al, 1998). In conclusion E-CD
appears to be of no significant prognostic value in predicting long-
term outcome of women with breast cancer in this series. 
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